Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study

INTRODUCTION: The Chinese Diabetes Society recommends basal insulin and glucagon-like peptide-1 receptor agonists as an add-on therapy to first-line oral antihyperglycemic drugs for people with type 2 diabetes (T2D). Fixed-ratio combination of insulin glargine 100 U/ml (iGlar) and lixisenatide (iGla...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Panpan, He, Xuemei, Gao, Xin, Shuai, Mengmeng, Schmider, Wolfgang, Jiang, Alex, Yang, Na, Shi, Aixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299984/
https://www.ncbi.nlm.nih.gov/pubmed/37329393
http://dx.doi.org/10.1007/s13300-023-01434-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299984/
https://www.ncbi.nlm.nih.gov/pubmed/37329393
http://dx.doi.org/10.1007/s13300-023-01434-0

Ejemplares similares